Safeguarding Potency:
Innovative Containment Strategies for HPAPI Manufacturing

The pharmaceutical and biotech industries are undergoing a significant transformation, driven by the rise of precision medicine, biologics, and targeted therapies. At the heart of this evolution lies a growing reliance on high potency active pharmaceutical ingredients (HPAPIs)—compounds that deliver therapeutic effects at extremely low doses. These ingredients are increasingly central to oncology, hormone therapies and rare disease treatments, and their use is expanding rapidly across both large pharmaceutical companies and emerging biotech firms.

As demand for HPAPIs accelerates, so too does the need for advanced containment strategies. Manufacturing these potent compounds requires not only scientific expertise but also purpose-built infrastructure, rigorous safety protocols and global regulatory alignment. For contract development and manufacturing organisations (CDMOs), containment is more than a compliance requirement – it is a strategic capability that enables innovation, protects workers and ensures product integrity.

This article explores the drivers behind the industry's shift toward HPAPIs, the containment challenges it presents and how CDMOs are responding with cutting-edge solutions that support pharmaceutical and biotech companies worldwide.

The Industry Shift: Why HPAPIs Are Surging

The global HPAPI market is projected to reach USD $31.5 billion by 2029, with more than 25% of drugs currently on the market formulated with HPAPIs. This growth is fuelled by several converging trends:

Oncology Pipeline Expansion

Cancer therapies increasingly rely on highly potent compounds to target specific cells with minimal off-target effects. HPAPIs are foundational to antibody-drug conjugates (ADCs), cytotoxic agents and hormone-based treatments. These therapies demand precise dosing and robust containment to ensure both efficacy and safety during manufacturing.

Personalised Medicine

As treatments become more tailored to individual patients, the need for small-batch, high-potency formulations grows. HPAPIs enable precise dosing and targeted delivery, making them ideal for personalised therapies. This shift requires CDMOs to offer flexible manufacturing solutions that can accommodate variable batch sizes and complex formulations.

Biotech Innovation

Start-ups and mid-sized biotechs are driving innovation in rare diseases and niche indications, often using HPAPIs in early-stage development. These companies typically lack internal manufacturing capacity and rely on CDMOs for technical expertise, containment infrastructure and regulatory support. The ability to scale quickly and safely is critical to their success.

Regulatory Pressure
Regulatory agencies such as the MHRA, EMA and FDA are tightening guidelines around occupational exposure limits (OELs), cross-contamination and facility design. Compliance is no longer optional – it is a prerequisite for market access. CDMOs must demonstrate robust containment capabilities to meet these evolving standards and support global product launches.

Globalisation of Drug Development
With clinical trials and product launches spanning multiple regions, pharmaceutical companies must ensure that HPAPI containment strategies meet diverse regulatory standards and cultural expectations. CDMOs with multi-site operations and harmonised quality systems are well-positioned to support global programmes.

Defining High Potency
HPAPIs are typically defined by their biological activity at low doses, with OELs at or below 10 µg/m³ over an 8-hour time-weighted average.

These compounds may also exhibit:

- High receptor selectivity, which increases therapeutic precision but also toxicity risk.
- Carcinogenic or mutagenic potential, requiring stringent handling protocols.
- Hormonal or steroidal activity, which can disrupt biological systems even at trace levels.
- Unknown toxicity profiles, particularly in novel compounds, necessitating conservative containment approaches.

To manage these risks, manufacturers use Operational Exposure Banding (OEB) systems that classify compounds from low to high potency. Compounds with a high OEB level, for example, require glovebox isolators, rapid transfer ports (RTPs) and closed transfer systems to ensure safe handling.

Containment Capability – The CDMO Response
CDMOs are responding to the HPAPI challenge by embedding containment into every aspect of their operations – from facility design to operator training. This holistic approach reflects a deep understanding of both the science and the operational realities of high-potency production.

Purpose-Built Facilities
Modern CDMO facilities are designed with containment in mind. Key features include:

- Isolators for dispensing, blending and milling operations, which prevent operator exposure and cross-contamination.
- Wash-in-place (WIP) systems, which automate cleaning and reduce manual intervention.
- HEPA-filtered HVAC systems with pressure differentials to maintain cleanroom integrity and prevent airborne contamination.

Modular GMP suites, which allow for scalable production and rapid reconfiguration based on project needs.

These design elements ensure that containment is not an afterthought – it is a foundational xprinciple that supports both safety and flexibility.

Advanced Equipment
Containment is also a function of equipment. CDMOs are investing in:

- Split butterfly valves for contained powder transfer between vessels.
- Tablet compression and capsule filling systems with integrated containment features.
- Flexible packaging lines capable of handling potent products without compromising operator safety.

This equipment enables safe, efficient processing while maintaining product quality and regulatory compliance.

Agile Process Design
HPAPI manufacturing often involves variability in particle size, solubility and stability. CDMOs address this through adaptable process design, using real-time analytics and flexible configurations to ensure consistency.

For example, oxygen-sensitive formulations may require nitrogen purging during bottling, while variable particle sizes may necessitate customised blending protocols. These solutions are developed through cross-functional collaboration and rigorous process development.

Operator Training and Culture
Containment is only as strong as the people who implement it. CDMOs invest in:

- Regular training on PPE, gowning and emergency protocols to ensure safe handling.
- Operator engagement in continuous improvement initiatives to identify and mitigate risks.
- Cross-functional collaboration between manufacturing, quality and engineering teams to maintain containment integrity.

This culture of safety ensures that containment is a shared responsibility – not just a technical requirement.

Global Impact
The rise of HPAPIs and the need for containment have profound implications for pharmaceutical companies worldwide.

Large Pharma
Global pharmaceutical companies are expanding their oncology and specialty pipelines, often outsourcing HPAPI manufacturing to CDMOs. They require partners who can:

- Meet global regulatory standards across multiple jurisdictions.
- Scale production efficiently while maintaining containment.
- Ensure data integrity, traceability and audit readiness.

Experienced CDMOs with multi-site operations and harmonised quality systems are well-positioned to support these needs.

For Biotech Innovators
Biotechs face unique challenges: limited internal capacity, tight timelines and evolving formulations. They need CDMOs that offer:

- Flexible batch sizes and rapid tech transfer capabilities.
- Collaborative problem-solving and transparent communication.
- Access to containment infrastructure without long lead times.

CDMOs that can adapt quickly and provide tailored support are essential to biotech success.

Regulators and Investors
Containment is increasingly viewed as a marker of quality and risk management. Facilities that lack robust containment may face delays, recalls or reputational damage. Investors and regulators are scrutinising CDMO capabilities more closely than ever, making containment a strategic differentiator.

Strategic Drivers Behind the Shift
Beyond therapeutic innovation, several macro-level drivers are accelerating the shift toward HPAPI containment:

Employee Safety and Retention
As awareness of occupational hazards grows, companies must demonstrate a commitment to employee safety. Robust containment systems reduce exposure risk, improve morale and support long-term employee retention.

Environmental Sustainability
Containment systems reduce waste, emissions and contamination risk. Technologies such as WIP and closed-loop systems support sustainability goals while maintaining safety and compliance. CDMOs are increasingly integrating environmental considerations into facility and process design.

Digital Transformation
Advanced monitoring systems, data analytics and automation are enhancing containment strategies. Predictive maintenance and real-time environmental monitoring are helping CDMOs optimise HPAPI production and reduce downtime.

Therapeutic Complexity
As drug formulations become more complex – combining multiple APIs, delivery systems and excipients – containment strategies must evolve to accommodate diverse manufacturing needs. CDMOs are developing modular solutions and investing in multi-functional equipment to meet these demands.

Looking Ahead: Scaling for the Future
As HPAPI demand grows, containment strategies must evolve. CDMOs are investing in:

- Expanded peptide and small molecule API capacity to support a broader range of therapies.
- Enhanced analytical infrastructure to ensure product quality and regulatory compliance.
- Digital tools for process monitoring and control, enabling proactive risk management.
- Talent development programmes to build the next generation of containment experts.

These investments position CDMOs to support the next generation of high-potency therapies – whether in oncology, neurology or beyond.

Conclusion
The pharmaceutical industry's shift toward HPAPIs is reshaping how drugs are developed, manufactured and delivered. Containment is no longer a niche concern – it is a strategic enabler of innovation, safety and global access.

For CDMOs, containment is built into the DNA of operations. Through purpose-built facilities, advanced equipment, agile processes and a culture of safety, they empower pharmaceutical and biotech companies to navigate the complexities of high-potency manufacturing.

As the industry continues to evolve, those who invest in containment will be best positioned to lead.

James Millar

James Millar, Operations Support Manager (Manufacturing Support), Almac Pharma Services. With over 10 years' experience, James leads operational support for manufacturing with a focus on equipment qualification, cleaning validation and process optimisation.